Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Apr 1, 2017
Filed with the SEC on May 5, 2017 and accepted by EDGAR at May 5, 2017, 09:43 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-04-01. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2017-01-01 to 2017-04-01 | $2.13bn | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2017-01-01 to 2017-04-01 | $215.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-01-01 to 2017-04-01 | $1.33bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-01-01 to 2017-04-01 | $622.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-01-01 to 2017-04-01 | $135.4m | us-gaap:InterestExpense |
| Income tax | 3 months2017-01-01 to 2017-04-01 | −$48.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-01-01 to 2017-04-01 | $551.4m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2017-01-01 to 2017-04-01 | $1.40 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-01-01 to 2017-04-01 | $1.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-01-01 to 2017-04-01 | 394,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2017-01-01 to 2017-04-01 | $361.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2017-01-01 to 2017-04-01 | $93.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2017-01-01 to 2017-04-01 | $59.1m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2017-01-01 to 2017-04-01 | $500.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-04-01 | $713.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-04-01 | $7.25bn | us-gaap:AssetsCurrent |
| Total assets | At period end2017-04-01 | $46.21bn | us-gaap:Assets |
| Current liabilities | At period end2017-04-01 | $5.30bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | At period end2017-04-01 | $1.88bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2017-04-01 | $21.80bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2017-04-01 | 391,219,918 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-17-000023. Last ingested by Listed: Nov 14, 2026, 12:05 ET. Listed shows no prices and gives no investment advice.